Induction of anti-tumour lymphocytes in cancer patients after brief exposure to supernatants from cultures of anti-CD3-stimulated allogeneic lymphocytes
1997

Inducing Anti-Tumor Lymphocytes in Cancer Patients

Sample size: 90 publication Evidence: moderate

Author Information

Author(s): CN Baxevanis, ML Tsiatas, NT Cacoullos, G Spanakos, C Liacos, I Missitzis, Si Papadhimitrioul, M Papamichail

Primary Institution: Hellenic Anticancer Institute, Athens, Greece

Hypothesis

Can supernatants from anti-CD3-stimulated lymphocytes induce tumor-reactive cytotoxic lymphocytes in cancer patients?

Conclusion

Supernatants from healthy donor-derived lymphocytes can activate tumor-reactive lymphocytes in cancer patients, enhancing their ability to kill tumor cells.

Supporting Evidence

  • ACD3S significantly enhanced NK and LAK cell-mediated cytotoxicity in cancer patients.
  • High levels of cytokines in ACD3S correlated with increased cytotoxicity.
  • ACD3S from healthy donors was more effective than that from cancer patients.
  • Short-term incubation with ACD3S was sufficient to activate tumor-reactive lymphocytes.
  • ACD3S can be easily collected and stored for future clinical use.

Takeaway

Researchers found that a special liquid from healthy people's blood can help cancer patients' immune cells fight tumors better.

Methodology

Cancer patients' PBMCs were incubated with supernatants from anti-CD3-stimulated healthy donor PBMCs for 3 hours to assess cytotoxicity against tumor cells.

Potential Biases

Potential bias in patient selection and the influence of prior treatments on immune response.

Limitations

The study primarily focused on a limited number of cancer types and may not generalize to all cancers.

Participant Demographics

120 men and 90 women, average age 57 years, with various types of cancer.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication